GSK (GSK) · Pharmaceuticals
GSK Q2 2026 earnings: summary, key numbers & outlook
Results filed 28 Jul 2026 · Quarter ended 30 Jun 2026
Press release ↗Investor relations ↗
Summaries and transcripts are machine-generated and can contain errors.
In brief
GSK launched an 'Accelerate Growth' programme, lifting planned phase III trial starts in 2026 to 20+ from 10, as it bets on a late-stage pipeline across oncology, respiratory, hepatology and vaccines.
GSK's growth came from Specialty Medicines. Long-acting HIV injectables delivered 80% of HIV growth, and Nucala, Benlysta and Jemperli all grew. Arexvy and meningitis vaccines also rose. The older respiratory portfolio shrank, with Trelegy hit by US Medicare benefit design changes and pricing pressure. GSK stopped camlipixant in refractory chronic cough after phase III results and bought two lung cancer medicines, Jideytro and neladalkib.
Management plans to speed up 7 late-stage assets across 18 indications. It will open a new R&D centre in Cambridge and fund this with a 3-year savings programme, aiming for sales above £40 billion by 2031. The tension is timing: the dolutegravir patent expires in 2028-2030, while the growth assets must prove themselves, and cost cuts must be reinvested without weakening launches.
No call transcript for this quarter, so this summary also draws on: Pulse 2 ↗.
Key numbers
- Turnover · GAAP
- £8.4 billion
- Total operating profit · GAAP
- 481.0M
- Total operating margin · GAAP
- 5.7%
- Total EPS · GAAP
- 10.8p
- Core EPS · non-GAAP
- 50.5p
- Core operating profit · non-GAAP
- 2.8B
- Free cash flow
- £2.0 billion
+5% AER; +5% CER
(76)% AER; (75)% CER
(19.6ppts) AER
(69)% AER and CER
9% AER and CER
6% AER; 7% CER
| Segment or metric | Value | Change |
|---|---|---|
| Specialty Medicines | £3.8 billion | +14% |
| HIV | £2.1 billion | +10% |
| Respiratory, Immunology & Inflammation | £1.1 billion | +19% |
| Oncology | £0.6 billion | +17% |
| Vaccines | £2.3 billion | +8% |
| Arexvy | £0.2 billion | +>100% |
| General Medicines | £2.3 billion | -9% |
| Trelegy | £0.8 billion | -7% |
Where each number comes from
- Turnover: “Total Q2 sales £8.4 billion +5% AER; +5% CER ● | Specialty Medicines sales £3.8 billion (+14%); Respiratory, Immunology & Inflammation £1.1 billion (+19%)”
- Total operating profit: “Total operating profit | 481 | (76) | (75) | 2,774 | (35) | (31) | Total operating margin % | 5.7% | (19.6ppts) | (19.3ppts)”
- Total operating margin: “Total operating profit | 481 | (76) | (75) | 2,774 | (35) | (31) | Total operating margin % | 5.7% | (19.6ppts) | (19.3ppts)”
- Total EPS: “Total EPS | 10.8p | (69) | (69) | 54.1p | (28) | (24) | Core operating profit | 2,800 | 6 | 7”
- Core EPS: “Core operating margin % | 33.3% | 0.4ppts | 0.6ppts | 34.0% | 0.7ppts | 1.2ppts | Core EPS | 50.5p | 9 | 9 | 97.1p”
- Core operating profit: “Total EPS | 10.8p | (69) | (69) | 54.1p | (28) | (24) | Core operating profit | 2,800 | 6 | 7 | 5,450 | 6 | 8”
- Free cash flow: “Cash generated from operations of £2.9 billion with free cash flow of £2.0 billion”
- Specialty Medicines: “Total Q2 sales £8.4 billion +5% AER; +5% CER ● | Specialty Medicines sales £3.8 billion (+14%); Respiratory, Immunology & Inflammation £1.1 billion (+19%)”
- HIV: “Oncology £0.6 billion (+17%); HIV sales £2.1 billion (+10%) ● | Vaccines sales £2.3 billion (+8%); Shingrix £0.9 billion (+3%)”
- Respiratory, Immunology & Inflammation: “Specialty Medicines sales £3.8 billion (+14%); Respiratory, Immunology & Inflammation £1.1 billion (+19%); Oncology £0.6 billion (+17%)”
- Oncology: “Respiratory, Immunology & Inflammation £1.1 billion (+19%); Oncology £0.6 billion (+17%); HIV sales £2.1 billion (+10%)”
- Vaccines: “HIV sales £2.1 billion (+10%) ● | Vaccines sales £2.3 billion (+8%); Shingrix £0.9 billion (+3%); Meningitis vaccines £0.5 billion (+21%)”
- Arexvy: “Meningitis vaccines £0.5 billion (+21%); and Arexvy £0.2 billion (+>100%) ● | General Medicines sales £2.3 billion (-9%)”
- General Medicines: “and Arexvy £0.2 billion (+>100%) ● | General Medicines sales £2.3 billion (-9%); Trelegy £0.8 billion (-7%)”
- Trelegy: “General Medicines sales £2.3 billion (-9%); Trelegy £0.8 billion (-7%) ● | Total operating profit -75% and Total EPS -69%”
Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.
Outlook
| Metric | Period | Outlook |
|---|---|---|
| Turnover growth | full-year 2026 (at CER) | 3% to 5% |
| Core operating profit growth | full-year 2026 (at CER) | 7% to 9% |
| Core EPS growth | full-year 2026 (at CER) | 7% to 9% |
| Core tax rate | full-year 2026 | 17.5% |
| Royalty income | full-year 2026 | £850-900 million |
| Dividend | full-year 2026 | 70p |
| Accelerate Growth annual savings | fully realised by 2029 | £1.9 billion |
Key takeaways
Long-acting HIV injectables now drive HIV growth
LAIs delivered 80% of total HIV growth and made up 35% of US HIV turnover, with Cabenuva and Apretude both growing strongly. This shift matters as dolutegravir loses exclusivity in 2028-2030.
GSK is accelerating seven late-stage assets
Acceleration spans 18 indications in Oncology, Respiratory, Hepatology and Vaccines, and planned phase III starts for 2026 rise to 20+ from 10. GSK has 62 assets in clinical development, 19 of them in phase III.
Lung cancer purchases and ADC data widen oncology
GSK acquired Jideytro (FDA approval) and neladalkib (PDUFA H2 2026), and Ris-Rez showed positive phase III overall survival data in China, described as a first for a B7-H3 ADC. Jemperli also has AZUR-1 data supporting rectal cancer reviews.
Camlipixant discontinued after phase III results
GSK decided not to progress camlipixant in refractory chronic cough following the CALM-1/2 phase III results. It took a £1.3 billion impairment, so the chronic cough bet ends and resources shift to other assets.
Established respiratory products face Medicare and pricing pressure
Trelegy fell 7% as US Medicare benefit design changes and channel mix pricing adjustments cut US volumes and price, while Europe and International grew. The General Medicines guidance now points to a mid-single to low-single digit decline.
Questions
What is GSK's main strategic move this quarter?
GSK launched an 'Accelerate Growth' programme to speed up 7 late-stage assets across 18 indications and now expects 20+ phase III starts in 2026, up from 10. It is funded by a 3-year programme targeting £1.9 billion of annual savings by 2029.
How is GSK preparing for dolutegravir losing exclusivity?
It is shifting HIV toward long-acting injectables, which delivered 80% of HIV growth, and building new growth drivers in oncology, respiratory and hepatology. Management expects stable to improving operating margin through 2028-2030 and sales of more than £40 billion by 2031.
Which products are growing fastest?
Arexvy, Cabenuva, Apretude, Ojjaara/Omjjara, Jemperli, Nucala and meningitis vaccines grew. Blenrep and Exdensur are early in launch, while Zejula and Trelegy declined.
What happened with camlipixant?
GSK decided not to progress further development of camlipixant in refractory chronic cough after the CALM-1/2 phase III results. It recorded an impairment of £1,334 million.
How did the US government agreement affect GSK?
GSK and ViiV Healthcare reached a definitive agreement providing Section 232 tariff relief through 20 January 2029, subject to final implementation. They signed Generous Model participation agreements with CMS effective 15 June 2026, and guidance includes the expected impact.
Documents
SEC filing